A board to discuss future MS therapies in early stage (Phase I or II) trials.
Etifoxine to target, a protein referred to as mitochondrial translocator protein (TSPO), had been previously identified but not linked to MS, an autoimmune disease that strips the protective fatty coating off nerve fibers of the brain and spinal cord. http://www.ucdmc.ucdavis.edu/publish/news/newsroom/7748
- Family Member
- Posts: 29
- Joined: Fri Apr 12, 2013 3:18 pm
Return to Drug Pipeline
Who is online
Users browsing this forum: No registered users